Journal
MOLECULAR CANCER
Volume 18, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s12943-019-1033-z
Keywords
N-6-methyladenosine; Cancer; RNA methylation; Prognosis; Growth; Metastasis
Categories
Funding
- National Natural Science Foundation of China [81873143, 81573747]
- Shanghai Science and Technology Commission Western Medicine Guide project [17411966500]
Ask authors/readers for more resources
N-6-methyladenosine (m(6)A) is identified as the most common, abundant and conserved internal transcriptional modification, especially within eukaryotic messenger RNAs (mRNAs). M(6)A modification is installed by the m(6)A methyltransferases (METTL3/14, WTAP, RBM15/15B and KIAA1429, termed as writers), reverted by the demethylases (FTO and ALKBH5, termed as erasers) and recognized by m(6)A binding proteins (YTHDF1/2/3, IGF2BP1 and HNRNPA2B1, termed as readers). Acumulating evidence shows that, m(6)A RNA methylation has an outsize effect on RNA production/metabolism and participates in the pathogenesis of multiple diseases including cancers. Until now, the molecular mechanisms underlying m(6)A RNA methylation in various tumors have not been comprehensively clarified. In this review, we mainly summarize the recent advances in biological function of m(6)A modifications in human cancer and discuss the potential therapeutic strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available